Testing JBI-802 for blood cell disorders with high platelets
Part of Blood & lymphatic clinical trials.
This study tests a new oral medication called JBI-802 to treat rare bone marrow disorders (myeloproliferative and myelodysplastic neoplasms) that cause abnormally high platelet counts. The goal is to evaluate whether the drug is safe and can help lower platelet levels and control disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have one of these diagnoses: Essential Thrombocythemia, Polycythemia Vera, myelofibrosis, or MDS/MPN (certain blood and bone marrow disorders), confirmed by bone marrow biopsy
- Your disease either failed previous treatment, you couldn't tolerate it, or your doctor believes no standard treatment will help
- You can swallow pills and are willing to have bone marrow biopsies during the study
- Your blood counts and organ function meet specific requirements (hemoglobin ≥9, certain white blood cell and platelet levels, normal liver and kidney function)
- You stopped any prior cancer treatments at least 1 week ago (4 weeks for interferon)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called BG-75202, alone or combined with other treatments, for myeloid malignancies (blood cancers affecting bone marrow cells) that have returned or stopped responding to previous treatment. The goal is to see if this drug can help control the cancer.
This trial tests a new drug, JNJ-90189892, for people with certain types of blood cancers (acute myeloid leukemia or higher-risk myelodysplastic neoplasms) that have come back or not responded to treatment. The goal is to see if the drug is safe and effective.
This trial tests a new drug, INCA035784, for people with myeloproliferative neoplasms (MPNs), a group of blood cancers. It may help if your MPN is called myelofibrosis (MF) or essential thrombocythemia (ET) and has a specific genetic change (CALR mutation), and you've already tried other treatments.
This trial tests a new drug called INCA036978 for people with a group of blood cancers called myeloproliferative neoplasms (MPNs), including myelofibrosis, polycythemia vera, and essential thrombocythemia. It aims to see if the drug is safe and works well.
This trial tests a daily pill called STP938 (dencatistat) for people with high-risk essential thrombocythemia (ET) who cannot take or have stopped responding to hydroxycarbamide. The goal is to see if STP938 can safely lower your platelet count and control the condition.
This study tests a drug called imetelstat in patients with rare blood disorders (CMML and MDS/MPN). The drug may help by stopping abnormal blood cells from growing and reduce symptoms like tiredness and enlarged spleen.
Hear when a new Myeloproliferative Neoplasms (MPN) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.